你所在的位置: 首页 > 正文

结直肠癌进入精准治疗时代 分子标志物检测率仍然较低

2019-07-25 点击:1768
经济日报 - 中国经济网

经济日报 - 中国经济网北京7月9日结直肠癌是困扰中国患者的最恶性癌症之一。通过准确的诊断和精确的治疗,医生可以优化治疗计划并延长患者的寿命。我国肠癌分子标志物检出率不到30%,有待提高。 7月8日,默克与金宇医药就结直肠癌基因检测达成战略合作协议,双方共同推动结直肠癌分子标志物检测的标准化和标准化。

近年来,结直肠癌的发病率持续上升,《2015年中国癌症统计数据》表明结直肠癌新病例数为376,300,结直肠癌患者数为191,000。根据2018年的国家癌症统计数据,结直肠癌的发病率排名第三,仅次于肺癌和胃癌。结直肠癌的早期进展缓慢,症状隐蔽和混乱,导致早期发现或注意力不足。临床上的大多数患者都处于中晚期阶段,这给治疗带来了巨大的挑战。

准确的治疗已经加剧了结直肠癌的治疗,为晚期转移性结直肠癌患者带来了更大的临床益处。北京大学国际医院副院长,癌症中心主任梁军说:提高患者的生存率是临床上最大的任务。目前,结直肠癌已进入精准治疗时代,基因检测技术可为医生提供宝贵的临床经验。指导基础,选择更合适的患者用药,并帮助诊所制定精确的治疗方案。近年来,国家健康保险已纳入多种抗癌药物,进口抗癌药物也实现零关税政策,但与欧美国家相比,国内基因检测能力仍存在较大差距。

In the《结直肠癌分子生物标志物检测专家共识》released in 2018, it is recommended to test the molecular markers of intestinal cancer (including RAS/BRAF) for patients with clinically diagnosed recurrent or metastatic colorectal cancer, to help predict the effect of drug therapy for colorectal cancer, and Predict disease prognosis. However, the detection rate of molecular markers of intestinal cancer (including RAS/BRAF) is only 20%-30% in patients with colorectal cancer, especially in second- and third-tier cities or underdeveloped areas, the detection rate is lower, affecting colorectal Diagnosis of cancer patients and selection of individualized treatment options. The reason is that, on the one hand, doctors have insufficient knowledge about the importance of detection of colorectal cancer molecular markers. In addition, there are practical problems such as inconsistent gene detection methods and processes, long detection cycles, and high prices. It is understood that there are still many hospitals in China that have not yet been able to establish a molecular pathology detection platform in the hospital. It is necessary to rely on out-of-hospital inspection for genetic testing, and the standard and standardized out-of-hospital inspection platform can meet the needs of hospital molecular pathology testing and ensure the quality of testing.

The Merck will cooperate with Golden Field Medicine to establish a regional academic platform to improve the knowledge of genetic testing and optimize the gene detection process for colorectal cancer. Luo Jieren, managing director of Merck China Biopharmaceutical Business, said that in cooperation with Golden Mile, Merck hopes to jointly promote the precise treatment of colorectal cancer and the formulation of industry norms.

"This time, combined with Merck, we continue to provide accurate and reliable detection technology, jointly transfer detection concepts, promote the standardization and standardization of the genetic detection process of colorectal cancer molecular markers (including RAS/BRAF), shorten the detection turnaround time, and reduce The cost of testing will benefit more patients with advanced colorectal cancer in China," said Yang Wanfeng, vice president of Jinyu Medical.

xx

日期归档
青海新闻网 版权所有© www.worldic-summit.com 技术支持:青海新闻网 | 网站地图